Dizziness

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”

Retrieved on: 
Tuesday, March 26, 2024
Connected, HIV-1, Amazon Prime Video, Breast milk, Face, Hypoesthesia, Patient, Chronic pain, Clostridioides, Heartburn, Lymph, Magnesium, Diarrhea, Myalgia, Spine, Allergy, Muscle weakness, Vonoprazan, Stomach, Vitamin, Dizziness, Potassium, Hip, Risk, Tongue, Chills, DTC, Safety, Food, PPI, Rash, Food and Drug Administration, GERD, Enzyme inhibitor, Skin, Esophagitis, HIV, Rilpivirine, Kidney, FDA, Esophagus, B-12, Weakness, Infection, Indigestion, Smart TV, Seizure, Inflammation, Polyp, Calcium, Extrapyramidal system, Bone fracture, Nausea, Spasm, Urine, Fever, Clostridioides difficile, Bleeding, Blood, Wrist, Blister, Vitamin B12, Human, Medicine, Pharmaceutical industry

FLORHAM PARK, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announces the launch of its new broadcast ad and full-scale, Direct-to-Consumer (DTC) campaign, “VOQUEZNA Can Kick Some Acid,” to raise awareness of its powerful first-in-class treatment and encourage people to speak to their doctor about this new treatment option. VOQUEZNA (vonoprazan) is indicated for the healing and maintenance of healing of all severities of Erosive Esophagitis (EE), also referred to as Erosive GERD, and for the relief of related heartburn. VOQUEZNA represents the first major innovation to the U.S. Erosive GERD market in over 30 years.1

Key Points: 
  • The campaign will also be featured on consumer-facing platforms across Facebook, Instagram, waiting room TVs in doctor offices, and digital banner ads.
  • “Phathom is excited to launch our first campaign directly to, and for, the people whose lives we strive to improve every day.
  • To view a video of the “VOQUEZNA Can Kick Some Acid” commercial, click here.
  • Talk with your healthcare provider about the possibility of fundic gland polyps if you have been on VOQUEZNA for a long time.

CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy

Retrieved on: 
Saturday, April 6, 2024
Guillain–Barré syndrome, Bone marrow, Medical College of Wisconsin, Encephalopathy, Survival, Immunotherapy, BCMA, Patient, Hypotension, Mortality, B-cell maturation antigen, Edema, Periodic breathing, Associate professor, Dexamethasone, Certification, Neutropenia, Dizziness, Risk, Headache, Chills, Myelodysplastic syndrome, Coagulopathy, DPD, Johnson & Johnson, Immune system, Effect, Fatigue, Thrombocytopenia, Food, Disease, Drive, Appetite, Lymphocytopenia, JNJ, Constipation, Multiple myeloma, Acute myeloid leukemia, CRS, Death, Hypersensitivity, Cytopenia, Cytokine release syndrome, ASCO, Use, Hematology, FDA, PVD, Annual general meeting, T cell, DSM-IV codes, Incidence, Tachycardia, Bortezomib, Diarrhea, Viral, Hope, United, Cough, Daratumumab, Nausea, Society, Division, Physician, Pharmaceutical industry

HORSHAM, Pa., April 5, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.1 With this approval, CARVYKTI® becomes the first and only B-cell maturation antigen (BCMA)-targeted therapy approved for the treatment of patients with multiple myeloma as early as first relapse.

Key Points: 
  • "This milestone underscores our commitment to improve outcomes for patients and transform the treatment of multiple myeloma with CARVYKTI," said Jordan Schecter, M.D., Vice President, Disease Area Leader, Multiple Myeloma, Johnson & Johnson Innovative Medicine.
  • CARVYKTI® is a cell therapy that works by harnessing a patient's immune system, or T cells, to fight the disease.
  • Treatment requires extensive training, preparation, and certification to ensure a positive experience for patients.
  • Since initial approval in February 2022, Johnson & Johnson has made significant advances in manufacturing to rapidly scale CARVYKTI® production.

The American Dream: Doctors Unite to Educate About Proactive Health on "The World Wellness Show"

Retrieved on: 
Thursday, March 14, 2024
Health, Dizziness, Medicine, Education, Knowledge, ALL, Social media, Interview, DSM-IV codes, Life expectancy, Chiropractic, Host, Neuropsychology, Peptide

GAINESVILLE, Fla., March 14, 2024 (GLOBE NEWSWIRE) -- The World Wellness Show expands collaborative movement towards proactive health to 137 countries with the help of top wellness experts.

Key Points: 
  • GAINESVILLE, Fla., March 14, 2024 (GLOBE NEWSWIRE) -- The World Wellness Show expands collaborative movement towards proactive health to 137 countries with the help of top wellness experts.
  • Doctors wanting to share "their messages" globally and create personalized content for their clinic's social media and websites can schedule their interview now at: www.TheWorldWellnessShow.com .
  • Trish Gleason, Host of the World Wellness Show, shared: “Together we can educate the world and spark a shift in wellcare from treatment to prevention.
  • Our goal is to spark a paradigm shift to how we perceive and prioritize health and move away from reactive treatments and towards proactive wellness practices.

 Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society

Retrieved on: 
Saturday, April 6, 2024
Biotechnology, Pharmaceutical, Health, Mental Health, BMY, Circulatory system, Head, Xerostomia, SIRS, Schizophrenia, Xanomeline, Dizziness, Glycated hemoglobin, Extrapyramidal symptoms, Weight gain, Patient, Syndrome, Constipation, Diarrhea, Bristol Myers Squibb, MD, Nature, Congress, Indigestion, Nausea, Prolactin, Safety, Vomiting, BMI, Schizophrenia International Research Society, Hypertension, Pharmaceutical industry

Bristol Myers Squibb (NYSE: BMY) today announced interim long-term safety, tolerability and metabolic outcomes data from its Phase 3 EMERGENT program evaluating KarXT (xanomeline-trospium) in adults with schizophrenia.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced interim long-term safety, tolerability and metabolic outcomes data from its Phase 3 EMERGENT program evaluating KarXT (xanomeline-trospium) in adults with schizophrenia.
  • “These long-term safety results and metabolic outcomes from the EMERGENT program are extremely encouraging, allowing us to further understand the tolerability profile of KarXT in people living with schizophrenia,” said Roland Chen , MD, senior vice president and head, Immunology, Cardiovascular and Neuroscience development, Bristol Myers Squibb.
  • In the pooled analysis, KarXT demonstrated a favorable impact on weight and long-term metabolic profile where most patients experienced stability or improvements on key metabolic parameters over 52 weeks of treatment.
  • In the long-term studies, KarXT was generally well-tolerated across 52 weeks of treatment, with a side effect profile consistent with prior trials of KarXT in schizophrenia.

Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE

Retrieved on: 
Monday, March 25, 2024
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Interest, Dizziness, Attack, Disease, PD, Webcast, Patient, HAE, Allergy, Quality of life, IND, Injection site reaction, Rash, Plasma kallikrein, Investment, Therapy, Hereditary angioedema, Safety, Charité, Pharmacokinetics, Pain, Multimedia, Pharmaceutical industry

Based on the positive results, Astria plans to advance STAR-0215 to Phase 3 development with trial initiation expected in Q1 2025 and top-line results expected by year-end 2026.

Key Points: 
  • Based on the positive results, Astria plans to advance STAR-0215 to Phase 3 development with trial initiation expected in Q1 2025 and top-line results expected by year-end 2026.
  • Initial safety and efficacy data from Q3M and Q6M dosing in the ALPHA-SOLAR trial are expected mid-2025.
  • Pending regulatory feedback, the Company expects to start a pivotal Q3M Phase 3 trial in Q1 2025, with top-line results expected by year-end 2026.
  • Interested parties may join the webcast via the Investors section of the Astria website, www.astriatx.com or with following the link https://lifescievents.com/event/astriatx/ .

Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease

Retrieved on: 
Wednesday, March 13, 2024
Science, Other Science, Research, Pharmaceutical, General Health, Health, Genetics, Other Health, Diagnosis, Alnylam Pharmaceuticals, Dizziness, Medication, Learning, Weakness, Genetic testing, Disease, TTR, Risk, Human, Patient, Common, Knowledge, Constipation, Diarrhea, Child, Amyloidosis, MBA, MPH, Heart, RNA interference, Carpal tunnel syndrome, Therapy, Multimedia, Family, Pharmaceutical industry

“Family history is considered one of the most important risk factors for health problems.

Key Points: 
  • “Family history is considered one of the most important risk factors for health problems.
  • “It took seeing nine doctors over seven years for me to finally receive a diagnosis of hATTR amyloidosis,” said Christine, a Family Health History Road Trip participant who is living with hATTR amyloidosis.
  • If I had, I could have potentially been diagnosed and started on a disease management plan much earlier.”
    With an inherited disease like hATTR amyloidosis that progresses rapidly, early diagnosis is crucial.
  • A genetic test can determine whether a person carries one of the more than 120 variants in the TTR gene associated with hATTR amyloidosis.

Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9

Retrieved on: 
Wednesday, March 13, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MSD, Hypersensitivity, Pregnancy, Wart, Head, Congress, Recombinant, Multiple endocrine neoplasia, Dizziness, Safety, Vain, Headache, Bruise, Public, Syncope, Ageing, Merck & Co., Cervical intraepithelial neoplasia, Vulvar intraepithelial neoplasia, Anal cancer, Virus-like particle, Observation, CIN, Thigh, Human, HPV, Plant, Vaginal intraepithelial neoplasia, Nausea, MRK, VLP, Investment, Immunity, Fever, Erythema, Vaccination, Injury, Vaccine, Allergy, Itch, AIN, Swelling

Separately, the company also plans to conduct clinical trials in both females and males to evaluate the efficacy and safety of a single-dose regimen of GARDASIL®9 (Human Papillomavirus 9-valent, recombinant), compared to the approved three-dose regimen.

Key Points: 
  • Separately, the company also plans to conduct clinical trials in both females and males to evaluate the efficacy and safety of a single-dose regimen of GARDASIL®9 (Human Papillomavirus 9-valent, recombinant), compared to the approved three-dose regimen.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
  • The latest addition to the pipeline employs the company’s proprietary virus-like particle (VLP) technology to incorporate additional VLPs for expanded HPV type coverage.
  • These randomized, double-blind, multi-year clinical trials will examine the short and long-term efficacy and immunogenicity of a single-dose of GARDASIL 9 versus the currently approved three-dose regimen.

FDA Approves New Antibiotic for Three Different Uses

Retrieved on: 
Wednesday, April 3, 2024
Daptomycin, Research, Hypersensitivity, Hypokalemia, Fungal infection, Aztreonam, Dizziness, Pneumonia, Survival, Dysgeusia, Potassium, Seizure, Abdominal pain, Dietary supplement, CABP, Headache, Patient, Public, Insomnia, Bacterial pneumonia, Food and Drug Administration, Animal, Bilirubin, Diarrhea, History, Mortality, Vancomycin, Leukopenia, Clostridioides, Human services, Injection site reaction, Nausea, Rash, Priority review, Bronchopneumonia, Skin, Fever, Heated tobacco product, Ceftriaxone, Safety, SAB, Anemia, Division, Phlebitis, Cosmetics, Vaccine, Infection, Food, Vomiting, Blood, Multimedia, FDA, Periodic breathing, ABSSSI, Pharmaceutical industry

"The FDA will continue our important work in this area as part of our efforts to protect the public health."

Key Points: 
  • "The FDA will continue our important work in this area as part of our efforts to protect the public health."
  • Zevtera's efficacy in treating SAB was evaluated in a randomized, controlled, double-blind, multinational, multicenter trial .
  • In the trial, researchers randomly assigned 390 subjects to receive Zevtera (192 subjects) or daptomycin plus optional aztreonam [the comparator] (198 subjects).
  • A total of 69.8% of subjects who received Zevtera achieved overall success compared to 68.7% of subjects who received the comparator.

Athletico Physical Therapy Opens in Grand Blanc, Michigan

Retrieved on: 
Thursday, March 28, 2024
Athletico Physical Therapy, Diagnosis, Clinic, Health, DPT, Dizziness, Therapy, Communication, Risk, Headache, Patient, Motion, Insurance, Life, Kroger, Dry needling, Pain, Starbucks, Rehabilitation, Nursing

GRAND BLANC, Mich., March 28, 2024 /PRNewswire/ -- Athletico Physical Therapy has opened a new location in Grand Blanc, Michigan, located across from Kroger and next to Starbucks on S. Saginaw Rd. This location offers convenient hours, including early morning, late evening and Saturday appointments, and does not require a referral or prescription to start treatment. To learn more, or to schedule a free assessment, visit www.athletico.com/GrandBlanc.

Key Points: 
  • GRAND BLANC, Mich., March 28, 2024 /PRNewswire/ -- Athletico Physical Therapy has opened a new location in Grand Blanc, Michigan, located across from Kroger and next to Starbucks on S. Saginaw Rd.
  • "I'm looking forward to providing quality physical therapy services to patients in the wonderful community of Grand Blanc," said Brad Bond, PT, DPT, Clinic Manager of Athletico Grand Blanc.
  • "Physical therapy has many benefits for individuals experiencing pain, decreased range of motion, strength or balance issues, and anything that impairs the quality and function of their life.
  • Services available at Athletico Grand Blanc include:
    Physical therapy – Our physical therapists treat you to reduce pain, improve or restore mobility, and to help you remain at your optimal health without further risk of injury.

Advisory - Only use authorized nicotine pouches as directed, and do not use unauthorized nicotine pouches

Retrieved on: 
Wednesday, March 20, 2024
Palpitations, Varenicline, Chest pain, Xerostomia, Dizziness, Weakness, Caregiver, Nervous, Indigestion, Sleep, Risk, Headache, NPN, Health, Nicotine, Angina, Internet, Stroke, Constipation, Smoke, Death, Heartburn, Health Canada, Arrhythmia, Nausea, Medicine, Nursing, Safety, Fatigue, Vomiting, Blurred vision, Allergy, Parent, Chronic pain, Advertising, Tobacco

Consuming multiple nicotine products at the same time, including authorized nicotine replacement therapy products, or varenicline (a prescription smoking cessation drug), may increase the adverse effects of nicotine.

Key Points: 
  • Consuming multiple nicotine products at the same time, including authorized nicotine replacement therapy products, or varenicline (a prescription smoking cessation drug), may increase the adverse effects of nicotine.
  • Use authorized nicotine pouches only as directed:
    To date, Health Canada has authorized only one nicotine pouch , containing 4 mg of nicotine per dose.
  • Nicotine replacement therapies, including nicotine pouches, are not authorized for recreational use or for use by nonsmokers and people under 18 years old.
  • There are no authorized nicotine pouches in Canada that contain more than 4 mg of nicotine per dose.